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Metformin, the only biguanide oral antidiabetic agent available, was first used 
clinically in the late 1950s. Metformin remains the first-line pharmacologic treat-
ment for type 2 diabetes patients. It can be used as a single agent or in combination 
therapy with other antidiabetes agents, including insulin. Metformin is absorbed 
predominately from the small intestine. It is rapidly distributed following absorp-
tion and does not bind to plasma proteins. It is excreted unchanged in urine. The 
elimination half-life of Metformin during multiple dosages in patients with good 
renal function is approximately 5 hours.
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1. Introduction
Metformin is a biguanide developed from galegine, aguanidine derivative 
found in Galega officinalis. Chemically, it is a hydrophilic base which exists at 
physiological pH as the cationic species [1, 2]. Metformin is the first-line drug 
for type 2 diabetes and the most commonly prescribed drug for this condition 
worldwide, either alone or in combination with insulin or other oral antidiabetes 
patients [3]. Metformin works by inhibiting the production of hepatic glucose, 
reducing intestinal glucose absorption and improving glucose uptake and utili-
zation. Besides lowering the blood glucose level, metformin may have additional 
health benefits, including weight reduction, lowering plasma lipid levels, and 
prevention of some vascular complications [4]. Metformin is also used for 
other indications such as polycystic ovary syndrome (PCOS) [5]. Metformin is 
increasingly recognized as a potential anticancer agent due to a reduced cancer 
incidence in diabetic patients treated with the drug, and recently, patients 
taking metformin were associated with a reduced risk of COVID-19-related 
mortality [6].
Metformin can be determined in biological fluids by various methods, mainly 
using high performance liquid chromatography (HPLC), which allows pharmaco-
kinetic studies in healthy volunteers and diabetic patients. Metformin disposition 
is apparently unaffected by the presence of diabetes and only slightly affected by 
the use of different oral formulations [2]. The oral absorption, hepatic uptake and 
renal excretion of metformin are mediated very largely by organic cation trans-
porters [7].
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2. Absorption
Metformin is orally administered in the dose range of 500 mg/b.i.d. or t.i.d. and 
up to a total of 2,550 mg/day or approximately 35 mg/kg/day. The immediate-release 
formulation of metformin is rapidly absorbed from the small intestine following an 
oral dose. It has an onset of action of about 1.5 hours, half-life in the circulation of 
about 1.5–4.9 hours, and duration of action of 16–20 hours [8]. About 20% of a total 
dose can be absorbed from the duodenum, up to 60% from the jejunum and ileum 
but only very small amounts from the colon. The rest is excreted in the feces [9]. 
Higher doses slow the rate of absorption and reduce the bioavailability [10]. Oral 
absorption of metformin from the immediate-release dosage forms is incomplete in 
man, with an estimated population mean of 55% for bioavailability [6]. Metformin 
has an absolute oral bioavailability of 40 to 60%, and gastrointestinal absorption is 
apparently complete within 6 hours of ingestion [11]. Its hydrophilicity is associated 
with the low intestinal and cell membrane permeability, which is recognized as a 
primary limiting step for metformin oral absorption [6].
The extended-release formulation has a similar onset of effect; however, its half-
life is 6.5 hours, and its duration of action is 24 hours. Therefore, it can be admin-
istered once daily. It is associated with fewer gastrointestinal side effects compared 
with the immediate-release formulation. The half-life of metformin may be pro-
longed in patients with renal impairment, resulting in a theoretical risk of the rare 
but fatal lactic acidosis. It has been suggested that this risk may be a consequence of 
the action of metformin to suppress gluconeogenesis resulting in the inhibition of 
lactic acid metabolism in the liver, and thus accumulation of lactate [8].
The intestinal absorption of metformin may be primarily mediated by plasma 
membrane monoamine transporter (PMAT). However, there is no in-vivo data 
which indicates the role of PMAT in the disposition and pharmacological effect of 
metformin [5].
3. Distribution
Metformin is rapidly distributed following absorption and does not bind to 
plasma proteins [11]. The volume of distribution has been reported to range from 
63 to 276 L after intravenous administration [1]. The concentration of metformin in 
the liver is three to five fold higher than that in the portal vein (40–70 μmol/L) after 
single therapeutic dose (20 mg/kg/day in humans or 250 mg/kg/day in mice) [3, 8], 
and metformin in general circulation is 10–40 μmol/L [8]. As the antihyperglycemic 
effect of metformin is mainly due to the inhibition of hepatic glucose output and 
the concentration of metformin in the hepatocytes is much higher than in the blood, 
the liver is therefore presumed to be the primary site of metformin function [12]. 
At usual clinical doses and dosing schedules of metformin hydrochloride tablets, 
steady-state plasma concentrations of metformin are reached within 24 to 48 hours 
and are generally <1 mcg/mL [4].
4. Metabolism and elimination
Metformin is not metabolized and is excreted unchanged in the urine, with a 
half-life of ~5 hrs. The population mean for renal clearance (CLr) is 510±120 ml/min. 
Active tubular secretion in the kidney is the principal route of metformin elimina-
tion [5]. The total amount of metformin excreted under steady-state conditions 
with 1 g BID is around 6 mmol. The average feces volume is 150 ml per 24 hours; the 
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calculated drug concentration in the distal colon is 40 mM. Not all of this may be 
free drug, as E. coli (with membrane potentials of −120 to −240 mV) may concen-
trate Metformin with subsequent block of its dihydrofolate reductase. The other 
6 mmol reach the general circulation via the portal vein and, passing the liver, are 
rapidly cleared by the kidneys. The plasma elimination rate, about 500 ml per min, is 
similar to the kidney plasma flow, indicating active secretion [9].
The factors probably contribute to high clearance of metformin include: the 
low molecular weight associated with a negligible plasma protein binding; the 
presence of transporters in the kidney; and the low lipid solubility which makes 
negligible the passive reabsorption. The clearance is reduced in proportion to 
the reduction of renal function [13]. Metformin is contraindicated if serum 
creatinine levels ≥1.5 mg/dL in males, and ≥1.4 mg/dL in females or abnormal 
creatinine clearance. It should not be initiated in patients 80 years of age unless 
measurement of creatinine clearance demonstrates that renal function is not 
reduced [14].
5. Therapeutics range
The therapeutic range of plasma concentrations of metformin is unclear; 
however, concentrations above 5 mg/L are considered elevated [15]. Metformin 
immediate release (IR) taken BID and metformin extended release (XR), taken 
once daily (QD) in the evening with a meal, have almost equal areas under the curve 
(AUCs) for the same total dose. Both formulations have similar efficacy and safety 
profiles [9].
Metformin accumulation is a risk factor for fatal lactic acidosis. Therefore, 
therapeutic drug monitoring of metformin is required as an effort to ascertain that 
metformin concentration is within the recommended therapeutic range [16]. It is 
suggested that the mean plasma concentrations of metformin over a dosage interval 
be maintained below 2.5 mg/L in order to minimize the development of this adverse 
effect [7].
6. Therapeutics monitoring
Administration of ≥ 900 mg/kg/day of metformin resulted in morbidity/mor-
tality and clinical signs of toxicity in rats. Increased incidence of minimal necrosis 
with minimal to slight inflammation of the parotid salivary gland for male rats 
given 1200 mg/kg/day, body weight loss and clinical signs in rats given ≥ 600 mg/
kg/day were observed. Metformin was also associated with evidence of minimal 
metabolic acidosis at doses ≥ 600 mg/kg/day in rats [17]. In a preclinical study, 
intravenous and intragastric administration of metformin produced a significant 
increases in lactate AUC at the higher metformin doses (500 and 750 mg/kg), but 
intra-ileum administration did not produce an increase in lactate AUC relative to 
vehicle at either dose [18].
Large overdoses of metformin can lead to lactic acidosis. Suicide with metformin 
is rare. Intake of 35 g of metformin has been shown to be lethal [19]. The clinical 
study observed that patients on treatment with metformin developed lactic acidosis 
with metformin levels ranging from 256 to 682 μmol/L. This indicates that high lev-
els of serum metformin are needed to cause lactic acidosis [20]. Metformin plasma 
levels >5 μg/mL are generally found when metformin is implicated as the cause of 
lactic acidosis [21]. Metformin plasma concentration levels do not exceed 5 μg/mL 
during controlled clinical trials, even at maximum doses [4]. Renal dysfunction, 
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sepsis, alcohol abuse, liver failure, radiologic contrast media administration, acute 
coronary syndrome, acute congestive heart failure, and shock increase the risk of 
metformin-related lactic acidosis [22].
Metformin plasma concentrations are approximately 2–4 fold higher in patients 
with moderate to severe renal impairment [21]. According to the Food and Drug 
Administration (FDA) recommendation, metformin is contraindicated in patients 
with an estimated glomerular filtration (eGFR) <30 mL/min/1.73 m2. Those with 
an eGFR between 30 and 45 mL/min/1.73 m2 should not be initiated on metformin. 
If a person’s eGFR falls between 30 and 45 mL/min/1.73 m2 and they are already 
treated with metformin, their provider should assess their risk and benefit associ-
ated with continued use [22].
Elderly patients, who often have reduced muscle mass, should have their 
creatinine clearance rate estimated before use. If the creatinine clearance rate is 
< 70–80 ml/min, metformin should not be given [23]. Because hepatic function 
impairment may significantly limit the ability to clear lactate, generally avoid 
using metformin in patients with clinical or laboratory evidence of hepatic disease. 
Caution patients against excessive alcohol intake, either acute or chronic, when 
taking metformin because alcohol potentiates the effects of metformin on lactate 
metabolism [24].
Gastrointestinal intolerance occurs quite frequently in the form of abdominal 
pain, flatulence, and diarrhea. Most of these effects are transient and subside 
once the dose is reduced or when administered with meals. Metformin may reduce 
vitamin B12 absorption due to calcium-dependent ileal membrane antagonism, an 
effect that can be reversed with supplemental calcium. This vitamin B12 deficiency 
is rarely associated with megaloblastic anemia [25].
7. Drug interaction
Metformin is a cation at physiological pH, as it is a strong base. Hence, the 
absorption, distribution and excretion of Metformin depend on the transporters 
such as organic cation transporters, multidrug and toxin extruders and plasma 
membrane monoamine transporter [26]. The oral absorption and hepatic uptake 
of Metformin are mediated possibly by organic cation transporters-1 and -3 and 
renal excretion of Metformin is largely mediated by Metformin transporters such 
as multidrug and toxin extruders-1 and 2-k and organic cation transporter 2 [5]. 
The drugs inhibiting the Metformin transporters could decrease the elimination 
of Metformin and increase its plasma concentrations leading to elevated risk of 
Metformin associated lactic acidosis [27].
Since Metformin is not metabolized, it is not expected to be involved in many 
drug–drug interactions. Thus, clinically significant drug interactions involving 
metformin are rare [25]. Some cationic agents such as amiloride, digoxin, mor-
phine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, 
and vancomycin that are eliminated by renal tubular secretion may compete with 
metformin for elimination. Concomitant administration of cimetidine, furosemide, 
or nifedipine may also increase the concentration of metformin [23, 25].
The studies found many drugs which interact with metformin, but only a 
small number of clinically relevant drugs were identified which include cimeti-
dine, contrast agents, dolutegravir, phenprocoumon, pyrimethamine, ranolazine, 
rifampicin, St John’s wort, trimethoprim, vandetanib and verapamil (Table 1) 
[26]. Verapamil remarkably decreases the glucose-lowering effect of metformin, 
without altering its pharmacokinetics. This is likely mediated by competitive 
5
Clinical Pharmacokinetics of Metformin
DOI: http://dx.doi.org/10.5772/intechopen.99343
inhibition of organic cation transporter 1 [28]. Metformin should be discon-
tinued at least 48 hours prior to the administration of iodinated contrast media 
which can produce acute renal failure and should only be restarted if renal func-
tion is normal [25]. Study observed that Metformin decreases the anticoagulant 
effect of phenprocoumon [29].








the excretion of 
metformin.
It increases exposure of 
Metformin and risk of 
Metformin associated 
lactic acidosis.
It is recommended 
to reduce the dose 
of Metformin 
when Cimetidine is 
co-prescribed.
Trimethoprim It inhibits Metformin 
elimination 
moderately through 
the inhibition of 
OCTs and MATEs.
It decreases Metformin 
clearance and increases 
plasma concentration.
Monitor carefully in 
patients with renal 
dysfunction or patients 
taking higher doses of 
Metformin
Rifampin Absorption
The mechanism may 
involve rifampin-
mediated induction 
of the OCT1 in the 
gastrointestinal tract.
Rifampin may increase the 
gastrointestinal absorption 
and therapeutic efficacy of 
metformin.
Close clinical monitoring 
of glycemic control is 
recommended, and the 
dosage of metformin may 
be adjusted as necessary.
Dolutegravir It is an inhibitor 
of both OCT2 and 
MATE1 transporters 
within the renal 
tubules.
It may increase the 
risk of hypoglycemia 
and GI intolerance due 
to increased plasma 
concentrations of 
Metformin.
Prescribers may adjust 
the Metformin dose 
to prevent intolerable 
adverse effects while 
prescribing both drugs.
Pyrimethamine Elimination
It decreases renal 
clearance of 
Metformin by 
the inhibition of 









adjustment should be 
considered.
Ranolazine Elimination
It may decrease 
the Metformin 
elimination through 
the inhibition of 
OCT2 transporter.
The plasma concentration 
of Metformin is elevated 
by the co-administration 
of Ranolazine.
This interaction is dose 
dependent and it is 
recommended that the 
daily dose of Metformin 
should not exceed 
1700 mg in patients 
taking Ranolazine 
1000 mg two times daily.
Vandetanib Elimination
Vandetanib is a 
potent inhibitor of 
MATE1 and MATE2K 
transporters.
Its co-administration 
with Metformin may 
result in increased 
plasma concentration 
of Metformin due to 
decreased elimination.
The patients receiving 
both drugs should be 
monitored carefully for 
Metformin toxicity.
OCT- Organic cation transporter; MATEs-Multidrug and toxin extruders; GI-Gastrointestinal
Table 1. 
Clinically a significant pharmacokinetic drug interactions of metformin.
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8. Conclusion
Metformin is widely used for the treatment of type 2 diabetes mellitus. 
Metformin is a highly ionized, water-soluble drug that is absorbed, distributed 
and eliminated by transporters [15]. It undergoes active tubular secretion in the 
kidney and is excreted unchanged in the urine. A change in pharmacokinetics can 
alter drug exposure and predispose the patient to either over- or under dosing, 
potentially resulting in adverse drug reactions or therapeutic failure [30]. Most of 
the possible drug interactions of Metformin occur through the inhibition of organic 
cation transporter and multidrug and toxin extruders and increase the risk of 
Metformin associated lactic acidosis. Metformin administration should be stopped 
and urgent medical attention given to the patients developing first signs of lactic 
acidosis such as severe vomiting and diarrhea [27].
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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